Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer

Chikazawa, Kenro; Imai, Ken; Ito, Takaki; Kimura, Azusa; Hiroyoshi, K O; Miho, Yokota; Kuwata, Tomoyuki; Konno, Ryo

doi:10.21873/invivo.12214

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inoue et al demonstrated in a randomized phase II trial comparing AMR with TOPO in patients with SCLC previously treated with platinum-containing chemotherapy that the median number of treatment cycles and median PFS in the AMR arm were 3 (range=1-7 months) and 3.5 months, respectively (5). Moreover, primary prophylaxis of PEG has been reported to increase relative dose intensity (RDI) of neoadjuvant/adjuvant FEC-100 (fluorouracil, epirubicin and cyclophosphamide) for breast cancer and to maintain RDI of carboplatin plus docetaxel or paclitaxel for ovarian cancer (21,22). Therefore, treatment continuation with primary prophylactic G-CSF support may have provided this improved efficacy in this study, but further large-scale studies are needed to elucidate them.…”

Section: Discussionmentioning

confidence: 99%

Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy

et al. 2021

View full text Add to dashboard Cite

Background/Aim: We evaluated the efficacy of primary prophylaxis with pegfilgrastim (PEG) for febrile neutropenia (FN) in small cell lung cancer (SCLC) patients receiving amrubicin (AMR). Patients and Methods: A retrospective cohort study was conducted in patients with SCLC receiving AMR as second-line therapy. Results: A total of 33 patients were treated with AMR (no PEG group), while 13 patients were treated with AMR plus prophylactic administration of PEG (PEG group). The severity of neutropenia was significantly reduced in the PEG group compared to the no PEG group (p=0.02). The incidence of FN in the no PEG and PEG groups was 27.3% and 7.7%, respectively. The time to development of FN tended to be longer in the PEG group compared to the no PEG group (p=0.132). Conclusion: Primary prophylaxis with PEG may be beneficial in reducing the risk of FN in patients with SCLC receiving AMR.

show abstract

Section: Discussionmentioning

confidence: 99%